
Go or no go? Sarepta’s gene therapy faces scrutiny
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.

Emerald gleams for Morphic
Ulcerative colitis data promise the efficacy and safety of Entyvio, but in a pill.

Takeda taps Innate for a new coeliac approach
The Japanese developer is an active name in the autoimmune condition, and with its first deal over ADCs it joins others with antibody approaches.

Go or no go? Seagen's Padcev eyes FDA approval
Seres and Pfizer are also set for upcoming FDA Pdufa decisions, and a panel is scheduled for Astrazeneca and Merck’s Lynparza.

AAD 2023 – Takeda outdoes Bristol’s Sotyktu
TAK-279 comes out on top in the battle of the Tyk2 inhibitors, but biologicals still rule.

Morphic looks to justify “oral Entyvio” excitement
Big hopes have built behind Morphic’s MORF-057 in ulcerative colitis, and a key trial reads out imminently.